Literature DB >> 8854854

Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection.

C J van der Laken1, O C Boerman, W J Oyen, M T van de Ven, R A Claessens, J W van der Meer, F H Corstens.   

Abstract

Recently, we demonstrated that radiolabelled interleukin-1alpha (IL-1) specifically accumulates in focal infection in mice through interaction with its receptor. Unfortunately, systemic side-effects of IL-1 limit its clinical application. We investigated whether this problem could be circumvented by using the interleukin-1 receptor antagonist (IL-1ra), an equally sized protein that binds to the same receptors as IL-1 without induction of biological effects. Biodistribution of 125I-IL-1 and 125I-IL-1ra was determined in Swiss mice with Staphylococcus aureus-induced abscesses in the left calf muscle at 4, 12, 24 and 48 h after injection of either 0.4 MBq 125I-IL-1 or 0.4 MBq 125I-IL-1ra. In vitro, the proteins displayed similar binding characteristics. High-performance liquid chromatographic analysis revealed a tendency for IL-1ra to associate with serum proteins. Both proteins rapidly cleared from most organs. However, the abscess uptake of 125I-IL-1ra was significantly lower than that of 125I-IL-1 at all time points (48 h p.i.: 0.06+/-0. 01%ID/g vs 0.60+/-0.04%ID/g; P<0.02). The abscess-to-contralateral muscle ratios did not exceed 15.5+/-2.9 for 125I-IL-1ra, while the ratios for 125I-IL-1 reached 46.9+/-5.7 at 48 h p.i. Despite similar in vitro receptor binding, the abscess uptake of IL-1ra was much lower than that of IL-1. The interaction of IL-1ra with serum proteins in vivo may reduce its availability for receptor binding in the infection. Although on theoretical grounds IL-1ra is very interesting, these characteristics will prevent its development as a clinically useful radiopharmaceutical to image infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8854854     DOI: 10.1007/bf01254480

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  Diagnosing infection in febrile granulocytopenic patients with indium-111-labeled human immunoglobulin G.

Authors:  W J Oyen; R A Claessens; J M Raemaekers; B E de Pauw; J W van der Meer; F H Corstens
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

2.  IL-1 and its receptor are translocated to the nucleus.

Authors:  B M Curtis; M B Widmer; P deRoos; E E Qwarnstrom
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

3.  Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.

Authors:  D S Wilbur; S W Hadley; M D Hylarides; P G Abrams; P A Beaumier; A C Morgan; J M Reno; A R Fritzberg
Journal:  J Nucl Med       Date:  1989-02       Impact factor: 10.057

4.  Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model.

Authors:  C J van der Laken; O C Boerman; W J Oyen; M T van de Ven; R A Claessens; J W van der Meer; F H Corstens
Journal:  Eur J Nucl Med       Date:  1995-11

5.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.

Authors:  E V Granowitz; R Porat; J W Mier; J P Pribble; D M Stiles; D C Bloedow; M A Catalano; S M Wolff; C A Dinarello
Journal:  Cytokine       Date:  1992-09       Impact factor: 3.861

6.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.

Authors:  D J Dripps; B J Brandhuber; R C Thompson; S P Eisenberg
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

Review 7.  Interleukin-1 and interleukin-1 antagonism.

Authors:  C A Dinarello
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

8.  Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction.

Authors:  R H Zubler; F Erard; R K Lees; M Van Laer; C Mingari; L Moretta; H R MacDonald
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

9.  Clinical experience with 99mTc-hexamethylpropylene-amineoxime for labelling leucocytes and imaging inflammation.

Authors:  A M Peters; H J Danpure; S Osman; R J Hawker; B L Henderson; H J Hodgson; J D Kelly; R D Neirinckx; J P Lavender
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

10.  Cloning and expression of murine interleukin-1 receptor antagonist in macrophages stimulated by colony-stimulating factor 1.

Authors:  H Matsushime; M F Roussel; K Matsushima; A Hishinuma; C J Sherr
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

  10 in total
  5 in total

1.  Characterization of 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways.

Authors:  Zhonglin Liu; Leonie Wyffels; Christy Barber; Li Wan; Hua Xu; Mizhou M Hui; Lars R Furenlid; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2012-06-28       Impact factor: 2.408

2.  A (99m)Tc-labeled dual-domain cytokine ligand for imaging of inflammation.

Authors:  Zhonglin Liu; Leonie wyffels; Christy Barber; Mizhou M Hui; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2011-04-21       Impact factor: 2.408

3.  Reduced adrenal response to bacterial lipopolysaccharide in interleukin-6-deficient mice.

Authors:  F H van Enckevort; C G Sweep; P N Span; P N Demacker; C C Hermsen; A R Hermus
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

Review 4.  Molecular imaging in atherosclerosis.

Authors:  Andor W J M Glaudemans; Riemer H J A Slart; Alessandro Bozzao; Elena Bonanno; Marcello Arca; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

5.  Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [¹⁸F]-IL1RA and PET imaging in rats.

Authors:  C Cawthorne; C Prenant; A Smigova; P Julyan; R Maroy; K Herholz; N Rothwell; H Boutin
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.